Shares of Teladoc Health Inc. (TDOC) plummeted 8.27% in Tuesday's trading session, despite the company reporting better-than-expected second-quarter revenue. The sharp decline suggests that investors may be focusing on other aspects of the company's financial performance and future outlook.

Teladoc announced Q2 revenue of $631.9 million, surpassing the IBES estimate of $622.7 million. However, the market's negative reaction indicates that this revenue beat was not enough to assuage investor concerns. The company also provided guidance for its third-quarter adjusted EBITDA, projecting a range of $56 million to $70 million, which may have fallen short of market expectations.

Prior to the earnings release, options market activity had implied a 9.9% move in Teladoc's share price post-earnings, with put options slightly outpacing calls. The actual 8.27% drop aligns closely with these market expectations, reflecting the significant uncertainty surrounding the company's financial results and future prospects. As the telehealth sector continues to evolve post-pandemic, investors appear to be closely scrutinizing Teladoc's ability to maintain growth and profitability in an increasingly competitive landscape.